These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group. Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805 [TBL] [Abstract][Full Text] [Related]
3. Transurethral resection and intravesical therapy of superficial bladder tumors. Herr HW Urol Clin North Am; 1991 Aug; 18(3):525-8. PubMed ID: 1877115 [TBL] [Abstract][Full Text] [Related]
4. [BCG versus photodynamic therapy (PDT) for nonmuscle invasive bladder cancer-a multicentre clinical phase III study]. Jocham D; von Wietersheim J; Pflüger H; Steiner H; Doehn C; Büttner H; Böhle A; Kausch I Aktuelle Urol; 2009 Mar; 40(2):91-9. PubMed ID: 19214951 [TBL] [Abstract][Full Text] [Related]
5. Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC genito-urinary group randomized phase 2 trial (30993). Oosterlinck W; Kirkali Z; Sylvester R; da Silva FC; Busch C; Algaba F; Collette S; Bono A Eur Urol; 2011 Mar; 59(3):438-46. PubMed ID: 21156335 [TBL] [Abstract][Full Text] [Related]
6. Epirubicin in treatment and recurrence prophylaxis of patients with superficial bladder cancer. Burk K; Kurth KH; Newling D Prog Clin Biol Res; 1989; 303():423-34. PubMed ID: 2780657 [No Abstract] [Full Text] [Related]
13. [Intravesical adjuvant chemotherapy for superficial bladder cancer -- results of a survey in Saxony]. Steinbach F; Schuster F Aktuelle Urol; 2005 Aug; 36(4):337-41. PubMed ID: 16110407 [TBL] [Abstract][Full Text] [Related]
14. Re: Willem Oosterlinck,Richard Sylvester, Marco Babjuk, et al. Should all patients receive an immediate chemotherapeutic drug instillation after resection of papillary bladder tumors? Eur Urol 2011;59:374-6. Gudjónsson S Eur Urol; 2011 Jul; 60(1):e2-3; author reply e4. PubMed ID: 21531071 [No Abstract] [Full Text] [Related]
15. The limits of bacillus Calmette-Guerin for carcinoma in situ of the bladder. Kim JC; Steinberg GD J Urol; 2001 Mar; 165(3):745-56. PubMed ID: 11176460 [TBL] [Abstract][Full Text] [Related]
16. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor. Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252 [TBL] [Abstract][Full Text] [Related]
17. Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. Sylvester RJ; van der Meijden AP; Witjes JA; Kurth K J Urol; 2005 Jul; 174(1):86-91; discussion 91-2. PubMed ID: 15947584 [TBL] [Abstract][Full Text] [Related]
18. Rationale for intravesical chemotherapy in the treatment and prophylaxis of superficial transitional cell carcinoma. Soloway MS; Jordan AM; Murphy WM Prog Clin Biol Res; 1989; 310():215-36. PubMed ID: 2505268 [TBL] [Abstract][Full Text] [Related]
19. Emerging targeted therapies for bladder cancer: a disease waiting for a drug. Dovedi SJ; Davies BR Cancer Metastasis Rev; 2009 Dec; 28(3-4):355-67. PubMed ID: 19997963 [TBL] [Abstract][Full Text] [Related]
20. [Transitional cell carcinoma in prostate after intravesical instillation of Bacillus Calmette-Guerin]. Ito Y; Nishiyama H; Higashi S; Kinoshita H; Ito N; Yamamoto S; Kamoto T; Ogawa O Hinyokika Kiyo; 2004 May; 50(5):335-8. PubMed ID: 15237488 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]